AcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of “Hold” by Brokerages
Shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have earned an average recommendation of “Hold” from the nine brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $6.25.
ACRX has been the subject of several recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. Royal Bank Of Canada set a $6.00 target price on shares of AcelRx Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 25th. Roth Capital reiterated a “buy” rating and issued a $12.50 target price on shares of AcelRx Pharmaceuticals in a research note on Thursday, August 10th. Stifel Nicolaus upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of AcelRx Pharmaceuticals in a research note on Friday, August 4th.
WARNING: “AcelRx Pharmaceuticals, Inc. (ACRX) Given Average Rating of “Hold” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/18/acelrx-pharmaceuticals-inc-acrx-given-average-rating-of-hold-by-brokerages.html.
In related news, CEO Vincent J. Angotti purchased 15,000 shares of the stock in a transaction on Thursday, August 24th. The shares were purchased at an average cost of $3.00 per share, with a total value of $45,000.00. Following the acquisition, the chief executive officer now directly owns 15,000 shares in the company, valued at $45,000. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Lawrence G. Hamel sold 10,161 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total transaction of $53,751.69. Following the completion of the transaction, the insider now directly owns 16,379 shares in the company, valued at $86,644.91. The disclosure for this sale can be found here. Over the last three months, insiders acquired 37,000 shares of company stock worth $112,280. Insiders own 28.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. bought a new position in AcelRx Pharmaceuticals in the 2nd quarter valued at about $530,000. Virtu KCG Holdings LLC raised its holdings in AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after acquiring an additional 101,742 shares during the period. LMR Partners LLP bought a new position in AcelRx Pharmaceuticals in the 2nd quarter valued at about $319,000. WealthTrust Axiom LLC raised its holdings in AcelRx Pharmaceuticals by 50.0% in the 2nd quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after acquiring an additional 70,000 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in AcelRx Pharmaceuticals by 6.6% in the 1st quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after acquiring an additional 6,942 shares during the period. 23.32% of the stock is currently owned by hedge funds and other institutional investors.
AcelRx Pharmaceuticals (NASDAQ:ACRX) remained flat at $1.75 during trading on Wednesday. The stock had a trading volume of 1,644,846 shares. The firm has a 50-day moving average price of $3.67 and a 200 day moving average price of $2.94. AcelRx Pharmaceuticals has a 12-month low of $1.70 and a 12-month high of $5.75. The stock’s market cap is $79.42 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. On average, equities research analysts forecast that AcelRx Pharmaceuticals will post ($1.12) earnings per share for the current year.
AcelRx Pharmaceuticals Company Profile
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.